R3 Vascular raised an $87 million Series B for its bioresorbable scaffold for peripheral artery disease.
Why it matters: While still in trial phase, R3 emerges as a potential competitor to Abbott, the first medtech to secure FDA approval for a dissolving stent to treat chronic limb-threatening ischemia.
